BioSpace News Archive

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing its Nano-Pulse Stimulation™ (NPS™) technology, today announced financial results for the first quarter of 2021.

Atrion Corporation announced that revenues for the quarter ended March 31, 2021 were $39.2 million compared with $43.6 million for the first quarter of 2020.

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced first quarter 2021 financial results.

AdaptHealth Corp., a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced that Steve Griggs, Co-Chief Executive Officer, Josh Parnes, President, and Jason Clemens, CFA, Chief Financial Officer, will meet virtually with investors and present at the following investor conferences:

Ended quarter with US$81.9 million in cash, cash equivalents and short-term investments; current cash position expected to be sufficient to fund operating plan until end of 2022

Q-State Biosciences (“Q-State”), a therapeutics and discovery technology company advancing programs for the treatment of central nervous system disorders, today announced a landmark achievement: the cumulative functional measurement of 50 million individual neurons using its biophysics-based optogenetic electrophysiology technology, Optopatch™.

Hanger, Inc., a leading provider of orthotic and prosthetic patient care services and solutions, announced that members of its management team will participate in presentations and meetings with institutional investors at the BofA Securities 2021 Healthcare Conference taking place virtually May 10-13, 2021.

Cutera, Inc. (CUTR) (“Cutera” or the “Company”), a leading provider of laser and other energy-based aesthetic systems for practitioners worldwide, today announced that it will present at the Virtual UBS Global Healthcare Conference

Psychemedics Corporation, the world’s largest provider of hair testing for drugs of abuse, announced financial results for the first quarter ended March 31, 2021.

New Amsterdam Sciences, a privately held company, announces the filing of the Company’s newly provided materials and data with the FDA’s coronavirus treatment acceleration program as a pre-Investigation New Drug Phase 2 submission.